254 related articles for article (PubMed ID: 30899979)
21. FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of
Løndalen A; Blakkisrud J; Revheim ME; Madsbu UE; Dahle J; Kolstad A; Stokke C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1902-1914. PubMed ID: 33196921
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
[TBL] [Abstract][Full Text] [Related]
23.
Dercle L; Seban RD; Lazarovici J; Schwartz LH; Houot R; Ammari S; Danu A; Edeline V; Marabelle A; Ribrag V; Michot JM
J Nucl Med; 2018 Jan; 59(1):15-24. PubMed ID: 28596157
[TBL] [Abstract][Full Text] [Related]
24. Prognostic role of pretreatment
Yang T; Liu S; Zuo R; Liang H; Xu L; Wang Z; Chen X; Pang H
BMC Med Imaging; 2023 Jan; 23(1):12. PubMed ID: 36681824
[TBL] [Abstract][Full Text] [Related]
25. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma.
Cazaentre T; Morschhauser F; Vermandel M; Betrouni N; Prangère T; Steinling M; Huglo D
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):494-504. PubMed ID: 19820933
[TBL] [Abstract][Full Text] [Related]
26. Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma.
Al Tabaa Y; Tchernonog E; Faurie P; Cottereau AS; Monjanel H; Bonnet A; Le Gouill S; Gyan E; Ghesquieres H; Mariano-Goulart D; Cartron G
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1705-1709. PubMed ID: 29679112
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of pretreatment ¹⁸F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using ¹³¹I-rituximab.
Lim I; Park JY; Kang HJ; Hwang JP; Lee SS; Kim KM; Choi TH; Yang SH; Kim BI; Choi CW; Lim SM
Acta Haematol; 2013; 130(2):74-82. PubMed ID: 23548464
[TBL] [Abstract][Full Text] [Related]
28. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
29. A retrospective head-to-head comparison of the Lugano classification and PERCIST for FDG-PET/CT response assessment in diffuse large B-cell lymphoma.
Nielsen NB; Gerke O; Nielsen AL; Juul-Jensen K; Larsen TS; Møller MB; Hildebrandt MG
Clin Physiol Funct Imaging; 2024 Jan; 44(1):70-78. PubMed ID: 37501554
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.
Milgrom SA; Dong W; Akhtari M; Smith GL; Pinnix CC; Mawlawi O; Rohren E; Garg N; Chuang H; Yehia ZA; Reddy JP; Gunther JR; Khoury JD; Suki T; Osborne EM; Oki Y; Fanale M; Dabaja BS
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):333-338. PubMed ID: 28068241
[TBL] [Abstract][Full Text] [Related]
31. Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients.
Bouard L; Bodet-Milin C; Bailly C; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Mahé B; Dubruille V; Blin N; Touzeau C; Gastinne T; Lok A; Bonnet A; Béné MC; Gouill SL; Moreau P; Kraeber-Bodéré F; Chevallier P
Biol Blood Marrow Transplant; 2019 May; 25(5):906-911. PubMed ID: 30481598
[TBL] [Abstract][Full Text] [Related]
32. Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
Barrington SF; Mir F; El-Galaly TC; Knapp A; Nielsen TG; Sahin D; Wenger M; Kostakoglu L; Trotman J; Meignan M
J Nucl Med; 2022 Aug; 63(8):1149-1154. PubMed ID: 34857656
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of [
Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131
[TBL] [Abstract][Full Text] [Related]
34. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
36. In-111 ibritumomab scintigraphy (planar and SPECT) and FDG PET/CT before Y-90 ibritumomab treatment in a patient with mantle cell lymphoma.
Jiménez-Bonilla JF; Quirce R; Banzo I; Martínez-Rodríguez I; Sainz-Esteban A; Barragán JE; López-Cordovilla JJ; Carril JM
Clin Nucl Med; 2007 Dec; 32(12):952-3. PubMed ID: 18030051
[TBL] [Abstract][Full Text] [Related]
37. Validation of the ΔSUV
Itti E; Blanc-Durand P; Berriolo-Riedinger A; Kanoun S; Kraeber-Bodéré F; Meignan M; Gat E; Gouill SL; Casasnovas RO; Bodet-Milin C
J Nucl Med; 2023 Nov; 64(11):1706-1711. PubMed ID: 37734837
[TBL] [Abstract][Full Text] [Related]
38. Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis.
Maturu VN; Rayamajhi SJ; Agarwal R; Aggarwal AN; Gupta D; Mittal BR
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Dec; 33(4):372-380. PubMed ID: 28079849
[TBL] [Abstract][Full Text] [Related]
39. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
40. Role of
Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
